News archive

 

dot IBD prospective cohort recruitment period prolongation is voted by the Steering Committee
(December 2016)

 

dot WP3 data integration innovative tool goes live internally for test runs
(November 2016)

 

dot ABIRISK is invited to speak at the TransMART Foundation Annual Meeting
(October 2016)

 

dot FIRST ABIRISK DRUG IMMUNOGENICITY CONFERENCE Innsbruck Medical University, Innsbruck, Austria - 1st April 2016

download pdf file Download the flyer

 

dot ABIRISK holds a Satellite Symposium on «Immunogenicity of Biopharmaceuticals» at the European Congress of Immunology in Vienna on September 6th
dot The final analyses plan of the rheumatoid arthritis cohort is given a go by the Steering Committee
(September 2015)

 

dot Recruitment of patients in the Inflammatory Bowel Disease cohort exceeds projections!
dot New British clinical centers join the prospective Rheumatoid arthritis cohort
dot ABIRISK sets out for the organization of an Open Scientific Meeting on the occasion of its General Assembly in March 2016, in Innsbruck, Austria
(August 2015)

 

dot ABIRISK project is granted a 9 months extension by IMI to maximize the productivity and impact of the project. New end date: 30th November 2017
dot Deloitte consultancy joins forces to help design and plan ABIRISK legacy
(July 2015)

 

dot ABIRISK welcome comments from the community on its white paper on Standardization of Terms and Definitions related to Immunogenicity of biopharmaceuticals
(June 2015)

 

dot First Juvenile Idiopathic Arthritis (JIA) patients enrolled in Greece
dot Two additional JIA clinical centers open in France
(November 2014)

 

dot ABIRISK Autumn Face-to-Face Steering Committee meeting in Copenhagen, hosted by our partner Novo Nordisk
dot Contract signed with CRO Sacura for Central Clinical Monitoring of ABIRISK prospective cohorts
(October 2014)

 

dot ABIRISK presentation at ProImmune Mastering Immunogenicity Conference, Boston, USA
dot ABIRISK presentation at Immunogenicity for Biologics, Berlin, Germany
(September 2014)

 

dot ABIRISK Project is a Hot Topic Session at the 2014 National Biotechnology Conference May 19-21, 2014, San Diego, California
(May 2014)

 

dot For prospective clinical trials, ABIRISK prepared 133511 tubes. Thank you to the GSK team that did the job
dot A whole session is dedicated to ABIRISK at the Coral Gables Symposium in Miami, USA , with WP1, WP2, and WP3 co-leaders invited to give an update on ABIRISK progress
dot First Rheumatoid Athritis patient enrolled in France
(April 2014)

 

dot ABIRISK General Assembly in Brussels rassembled over 100 participants, with a whole day dedicated
to poster sessions and oral presentations by ABIRISK junior scientists
(March 2014)

open image file View the gallery

 

dot Gabriele Reichmann from the Paul Erlich Institute, Germany joins ABIRISK Scientific Advisory Board
(February 2014)

 

dot First Multiple sclerosis patient enrolled in Austria
dot First Inflammatory Bowel disease patient enrolled in Israel
(January 2014)

 

dot PREDICTION OF IMMUNOGENICITY: THE FUTURE IN VIEW CORAL GABLES SYMPOSIUM (Miami, April 24-26, 2013)

 

dot EPMT & SC Meetings (September 2012)

 

event WP1 Assay Workshop (December 4th, 2012)

 

download pdf file March 2012 - Kick-off meeting fact sheet

open image file March 2012 - Kick-off meeting team photo